[1] ZHANG YanWANG LinXIAO HongyuLEI YuanlinZHOU NanaHAN Ru,.Current Research Status of Effects of Traditional Chinese and Western Medicine on Serum B-type Brain Natriuretic Peptide Levels [J]. Modern Traditional Chinese Medicine, 2024, (02): 8-13. [doi: 10.13424/j.cnki.mtcm.2024.02.002]
Current Research Status of Effects of Traditional Chinese and Western Medicine on Serum B-type Brain Natriuretic Peptide Levels
- Article number:
- 1672-0571(2024)02-0008-06
- Keywords:
- Key words:BNP; Heart failure; β Receptor blockers; ACEI; Diuretics; Traditional Chinese medicine
- ZTFLH:
- R256.2
- Code:
- A
- Abstract:
- Abstract：B-type natriuretic peptide (BNP) and N-terminal pro brain natriuretic peptide (NT pro BNP) in the family of natriuretic peptides are currently the most widely used quantitative biomarkers for the diagnosis，clinical evaluation，and prognosis of heart failure.However，it has been found in clinical practice that BNP often cannot accurately reflect the severity of heart failure.Western medicine（β Receptor blockers，angiotensin-converting enzyme inhibitors，diuretics，antiarrhythmic drugs and metabolic and hormonal drugs)，as well as traditional Chinese medicine (compound and monomer)，may all affect plasma BNP concentration.Through literature research，the article analyze and explore possible drug factors that may intervene in BNP levels for peer reference.
References:
［1］张永珍,范媛媛.心力衰竭通用定义和分类解读［J］.中国心血管杂志,2021,26(5):409-412
［2］McDonagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure［J］.European Heart Journal,2021,42(36):3599-3726.
［3］王华,李莹莹,柴坷,等.中国住院心力衰竭患者流行病学及治疗现状［J］.中华心血管病杂志,2019,47(11):865-874.
［4］Rubattu S,Stanzione R,Cotugno M,et al.Epigenetic control of natriuretic peptides:implications for health and disease［J］.Cellular and Molecular Life Sciences,2020,77(24):5121-5130.
［5］Qin LM,Liu XH,Li Y.Correlation of serum BNP and ET-1 levels with cardiac pump function and ventricular remodeling in patients with heart failure［J］.Cellular and Molecular Biology,2020,66(3):125-131.
［6］Januzzi JL Jr,Zannad F,Anker SD,et al.Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-reduced trial［J］.Journal of the American College of Cardiology,2021,78(13):1321-1332.
［7］Bauer S,Strack C,cer E,et al.Evaluation of a multimarker panel in chronic heart failure:a 10-year follow-up［J］.Biomarkers in Medicine,2021,15(18):1709-1719.
［8］王华,柴坷,杨杰孚.2021年心力衰竭诊治进展［J］.中国心血管病研究,2021,19(12):1067-1071.
［9］Fukuta H,Goto T,Wakami K,et al.Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction:a meta-analysis of randomized controlled trials［J］.Heart Failure Reviews,2021,26(1):165-171.
［10］Olsson LG,Swedberg K,Cleland JGF,et al.Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker:results from the Carvedilol Or Metoprolol European Trial (COMET) trial［J］.European Journal of Heart Failure,2007,9(8):795-801.
［11］毛文娟.β受体阻滞剂治疗心力衰竭合并房颤患者的疗效及安全性［J］.实用临床医药杂志,2019,23(2):33-36.
［12］张睿,刘宏扬.美托洛尔与曲美他嗪治疗冠心病合并心力衰竭的临床疗效［J］.中国卫生标准管理,2021,12(16):107-110.
［13］邓敏文.倍他乐克治疗慢性充血性心力衰竭的临床疗效观察［J］.当代医学,2015,21(26):124-125.
［14］贾魁,李志娟,邢适颖.β受体阻滞剂治疗对慢性心力衰竭患者的影响研究［J］.数理医药学杂志,2021,34(4):555-557.
［15］Garvin AM,Khokhar BS,Czubryt MP,et al.RAS inhibition in resident fibroblast biology［J］.Cellular Signalling,2021,80:109903.
［16］Fudim M,Sayeed S,Xu HL,et al.Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction［J］.Circulation Heart Failure,2020,13(4):e006645.
［17］Kim S,Yoshiyama M,Izumi Y,et al.Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling,cardiac function,and survival in rat heart failure［J］.Circulation,2001,103(1):148-154.
［18］Yan XW,Xu DL,Huang J,et al.Effect of benazepril on cardiac function in Chinese patients with chronic heart failure:a meta-analysis of randomized controlled trials［J］.Zhonghua Yi Xue Za Zhi,2014,94(37):2907-2913.
［19］吴秀娟,张毅.血管紧张素转化酶抑制剂治疗老年人慢性心力衰竭的有效性与安全性分析［J］.实用临床医药杂志,2014,18(15):56-58.
［20］焦天锐,舒娜,陈慧敏,等.依那普利对心力衰竭患者心功能及心电图变化的影响［J］.黑龙江中医药,2021,50(1):420-421.
［21］Felker GM,Ellison DH,Mullens W,et al.Diuretic therapy for patients with heart failure:JACC state-of-the-art review［J］.Journal of the American College of Cardiology,2020,75(10):1178-1195.
［22］Kapelios CJ,Laroche C,Crespo-Leiro MG,et al.Association between loop diuretic dose changes and outcomes in chronic heart failure:observations from the ESC-EORP Heart Failure Long-Term Registry［J］.European Journal of Heart Failure,2020,22(8):1424-1437.
［23］Buggey J,Mentz RJ,Pitt B,et al.A reappraisal of loop diuretic choice in heart failure patients［J］.American Heart Journal,2015,169(3):323-333.
［24］Ng TMH,Grazette LP,Fong MW,et al.Tolvaptan vs.furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF)［J］.ESC Heart Failure,2020,7(4):1927-1934.
［25］肖国霞,陈礼学,熊昌,等.联合使用托伐普坦治疗慢性心力衰竭的疗效观察［J］.当代医学,2021,27(10):56-58.
［26］Soylu K,Cerik IB,Aksan G,et al.Evaluation of ivabradine in left ventricular dyssynchrony and reverse remodeling in patients with chronic heart failure［J］.Journal of Arrhythmia,2020,36(4):762-767.
［27］Chen C,Kaur G,Mehta PK,et al.Ivabradine in cardiovascular disease management revisited:a review［J］.Cardiovascular Drugs and Therapy,2021,35(5):1045-1056.
［28］李谌.伊伐布雷定对缺血性心肌病伴心力衰竭患者的治疗效果观察［J］.中外医学研究,2021,19(25):74-76.
［29］Jackson AM,Dewan P,Anand IS,et al.Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF［J］.Circulation,2020,142(11):1040-1054.
［30］许朝霞.达格列净对2型糖尿病合并心力衰竭患者心功能与血清学指标的影响［J］.现代医学与健康研究电子杂志,2021,5(12):5-7.
［31］程康宁,任波.参麦注射液联合米力农治疗急性心力衰竭的疗效分析［J］.中国现代医学杂志,2021,31(14):92-96.
［32］林朝章.甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效探究［J］.山西医药杂志,2021,50(14):2195-2197.
［33］彭玉霞,卢桂林,张斌霞.中医药治疗慢性心力衰竭的研究进展［J］.中国中医急症,2020,29(2):373-376.
［34］孙梓宜,张天雅,王子涵,等.中医药治疗慢性心力衰竭的网络药理学研究进展［J］.中西医结合心脑血管病杂志,2022,20(21):3922-3925.
［35］章轶立,王娟,李园,等.芪参益气滴丸治疗慢性心力衰竭(气虚血瘀证)的Meta分析［J］.中国实验方剂学杂志,2019,25(21):162-169.
［36］张丽丽,韩冰.真武汤联合血府逐瘀汤方案对冠心病慢性心衰患者的治疗作用研究［J］.系统医学,2021,6(7):47-49.
［37］杨英俏.柴胡桂枝干姜汤治疗慢性心衰患者的效果观察［J］.当代医学,2021,27(3):116-118.
［38］Tang B,Zhang JG,Tan HY,et al.Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure［J］.Bioscience Reports,2018,38(3):BSR20171036.
［39］蔡镇.中药人参煎剂对慢性心力衰竭患者心功能及血浆脑钠肽水平的影响［J］.中医药信息,2016,33(1):56-59.
［40］Liu ZH,Liu HB,Wang J.Astragaloside IV protects against the pathological cardiac hypertrophy in mice［J］.Biomedicine & Pharmacotherapy,2018,97:1468-1478.
［41］王丽莉.黄芪甘草联用治疗慢性心衰患者的临床疗效观察［J］.中西医结合心血管病电子杂志,2020,8(33):165-166.
［42］李毓娟,朱洪斌,赵小瑞,等.丹参酮ⅡA应用于老年充血性心衰的疗效观察［J］.中国老年保健医学,2019,17(3):56-59.
［43］尹娅,潘沅,周宏伟,等.BNP和NT-proBNP在新生儿心血管疾病中的应用进展［J］.检验医学,2023,38(6):518-523.
［44］李燕,刘大军.BNP、NT-proBNP研究状况及进展［J］.实用药物与临床,2021,24(12):1133-1136.
［45］Rrth R,Jhund PS,Yilmaz MB,et al.Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction［J］.Circulation Heart Failure,2020,13(2):e006541.
［46］代雷阳,钱净,张鸿伟,等.心脏标志物的临床应用进展［J］.医学综述,2017,23(12):2323-2327.
Memo
基金项目：西安市科技计划项目［2019114613YX001SF044(7)］